KROS Keros Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1664710 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-83.4%
TTM net income YoY-195.8%
TTM EPS YoY-248.7%
Revenue 3-yr CAGR1,616.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-181.3%
Net margin-152.7%
FCF margin-119.4%
EBITDA margin-177.3%
Returns
ROE-12.6%
ROA-11.8%
ROIC (approx.)-389.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets9.2%
Debt / equity0.00x
Current ratio18.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $40.01M | $0 | $32,000 | $380,000 | $14.12M | $18.17M | $211.19M | $0 |
| R&D expense | $20.49M | $22.33M | $16.10M | $17.91M | $19.52M | $43.50M | $48.71M | $45.63M |
| SG&A expense | $6.70M | $8.61M | $10.15M | $11.74M | $10.13M | $14.48M | $10.50M | $10.66M |
| Operating income | $12.82M | -$30.94M | -$25.88M | -$29.27M | -$15.38M | -$39.82M | $152.04M | -$53.25M |
| Pretax income | $14.93M | -$28.71M | -$23.71M | -$24.98M | -$8.70M | -$32.92M | $158.49M | -$45.73M |
| Income tax | $772,000 | $0 | $0 | -$1.51M | -$1.42M | -$2.22M | $10.04M | $300,000 |
| Net income | $14.15M | -$28.71M | -$23.71M | -$23.46M | -$7.28M | -$30.70M | $148.45M | -$46.03M |
| EBITDA | $13.20M | -$30.54M | -$25.47M | -$28.87M | -$14.99M | -$39.45M | $152.38M | -$52.92M |
| EPS (basic) | 0.71 | -1.45 | -1.21 | — | -0.18 | -0.76 | 3.66 | — |
| EPS (diluted) | 0.70 | -1.45 | -1.21 | — | -0.18 | -0.76 | 3.62 | — |
| Weighted avg. shares (diluted) | 20.34M | 19.80M | 19.63M | — | 40.62M | 40.61M | 41.02M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $259.46M | $257.61M | $281.50M | $287.42M | $693.47M | $690.22M | $720.54M | $561.38M |
| Receivables | $20.00M | $0 | $400,000 | $3.57M | $3.49M | $15.82M | $17.29M | $2.74M |
| Current assets | $287.63M | $266.88M | $290.68M | $315.43M | $719.31M | $732.81M | $759.51M | $588.89M |
| PP&E, net | $3.39M | $3.71M | $3.96M | $4.30M | $4.56M | $4.84M | $4.47M | $4.24M |
| Total assets | $307.37M | $287.60M | $312.29M | $338.02M | $742.78M | $757.16M | $784.56M | $615.89M |
| Current liabilities | $15.86M | $12.15M | $12.85M | $20.41M | $24.09M | $34.71M | $39.38M | $27.45M |
| Total liabilities | $28.27M | $25.28M | $26.66M | $34.89M | $39.20M | $50.43M | $55.69M | $44.33M |
| Shareholders' equity | $279.10M | $262.32M | $285.63M | $303.13M | $703.58M | $706.73M | $728.87M | $571.55M |
| Shares outstanding | 19.83M | 19.83M | 19.73M | 19.54M | 40.63M | 40.62M | 40.56M | 40.55M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.39M | -$20.42M | -$3.53M | -$27.29M | $3.25M | -$29.62M | $161.17M | -$46.01M |
| Capital expenditure | $59,000 | $155,000 | $73,000 | $134,000 | $132,000 | $720,000 | $565,000 | $289,000 |
| Free cash flow | $3.33M | -$20.58M | -$3.60M | -$27.43M | $3.12M | -$30.34M | $160.61M | -$46.30M |
| Investing cash flow | -$59,000 | -$155,000 | -$73,000 | -$134,000 | -$132,000 | -$720,000 | -$565,000 | -$289,000 |
| Financing cash flow | -$1.47M | -$3.31M | -$2.32M | -$378.63M | $140,000 | $17,000 | $4,000 | $75.54M |
| Depreciation & amortization | $384,000 | $402,000 | $403,000 | $400,000 | $395,000 | $370,000 | $344,000 | $332,000 |
| Stock-based compensation | $4.20M | $5.38M | $6.20M | $7.30M | $3.99M | $8.54M | $8.86M | $9.20M |
| Share buybacks | — | — | — | $375.00M | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.